Abbott has secured the CE mark in Europe for its Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a device intended to treat peripheral artery disease (PAD) below the knee.

This system is designed to maintain arterial openness and deliver the drug everolimus to aid vessel healing before dissolving over time.

Traditionally, Europeans with PAD have been treated with balloon angioplasty, which involves using a catheter to insert a small balloon into the blocked artery to restore blood flow. However, Abbot states that this method often results in re-blockage, necessitating further interventions.